US/UK/Canada

Share

Contacts

  • Leona Minellas

    Communication Director


    07311 823947
  • Media enquiries

    • Links

    Quotes

    Tau pathology of the disease is now recognized as an important target for treatment, and it is encouraging that cognitive improvement is seen at such an early stage of the disease with a drug targeting Tau. The field has focused mainly on amyloid as a target for early intervention. Our data are consistent with the evidence that Tau pathology begins at least 20 years before clinical symptoms appear and is a viable first-line target for treatment.
    Professor Claude Wischik, Executive Chairman and co-founder, TauRx
    These data support our ability to pursue regulatory submissions. We look forward to making a significant difference addressing this global unmet need with a medication that is affordable, easy to administer, and safe. I’m very pleased to be joining the team and supporting the work we’re undertaking to achieve our mission of bringing treatments to people affected by neurodegenerative diseases caused through protein aggregation – Alzheimer’s is just the beginning.
    Dr Richard Stefanacci, Chief Medical Officer, TauRx
    “We recognise and publicly thank the incredible commitment from participants and partners involved in LUCIDITY. Our scientific focus on the role of tau pathology in neurodegenerative disease with support from our shareholders and team has enabled us to reach this important milestone.”
    Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx
    Pick a time period -
    Tags ( Active)

    TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

    · For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals · For people with mild to moderate Alzheimer’s, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with AD · HMTM is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities · TauRx will present the Phase 3 findings at the Clinical Trials in Alzheimer’s Disease (CTAD)

    TauRx Pharmaceuticals lights up Aberdeen for World Alzheimer’s Day

    For the second year, Aberdeen landmark, Marischal College, has today been lit up purple to mark World Alzheimer’s Day as part of a wider campaign organised by TauRx Pharmaceuticals and GT Diagnostics to promote support for the dementia community.Rebecca Andersen, Head of Commercial and Communications at TauRx, a global leader in tau-based research, said: “This year, World Alzheimer’s Month is shining a light on the importance of supporting people living with dementia and their families following a diagnosis. “TauRx and its scientists have been researching one of the key pathologies of

    TauRx and AFC Community Trust team up to host Memory Walk for dementia community

    TauRx, a global leader in tau-based Alzheimer’s disease research, and Aberdeen FC Community Trust, partner charity to Aberdeen Football Club, have partnered to host a ‘Memory Walk’ in support of Alzheimer Scotland and World Alzheimer’s Month in September.The memory walk will bring together local life sciences companies, dementia charities and the community to show support for those living with dementia across the North East of Scotland. Taking place in Duthie Park on Sunday 18 September, the walk will start at 11am outside the botanical gardens and is free for people of all ages and

    Tau-targeting Alzheimer’s treatment, HMTM, moving toward regulatory submission based on initial data from TauRx’s LUCIDITY trial

    · LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer’s based on published research · Safety profile is favourable and consistent with previous HMTM studies · TauRx will now pursue regulatory submission and coverage for HMTMTauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer’s, today announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY (NCT03446001). TauRx’s lead investigative oral

    TauRx’s late-stage clinical trial reaches new milestone

    TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease (AD) research, has announced that the last patient has completed treatment in the blinded phase of their late-stage phase three clinical trial, Lucidity.This significant milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine top line results on the safety and efficacy of Hydromethylthionine mesylate (which TauRx refers to under the chemical abbreviation, HMTM). The top line results are due to be announced in May. Professor Claude Wischik, Executive

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Twitter

    Youtube